Edinburgh-based medtech Manus develops a digital pen to detect Parkinson’s disease, bags £1.2M funding

It is estimated that around 145,000 people live with Parkinson’s in the UK. To help the same and detect the early signs of the disease, Edinburgh medtech company Manus Neurodynamica Limited (“Manus”), has closed a £1.2M funding round to support the launch of its digital pen which provides an early warning of Parkinson’s disease and other neurological conditions.

Manus secured funding from the North East Innovation Fund backed by the European Regional Development Fund and managed by Northstar Ventures profit with purpose investor SIS Ventures and Old College Capital, the University of Edinburgh’s venture fund.

This funding round comes after the £750K investment closed by the company in May last year, which was led by HealthTech investors Par Equity along with support from the Scottish Investment Bank, the investment arm of Scottish Enterprise, and Old College Capital. With this, the overall investment in the medtech company accounts to £5M.

With this latest funding secured, Manus is rolling-out its NeuroMotor PenTM sometime later this year.

Read more HERE.